Belite Bio, Inc. ADR (BLTE) Price & Analysis

Compare

36 Followers

BLTE Stock Chart & Stats

Day’s Range― - ―

52-Week Range$43.70 - $86.53

Previous CloseN/A

Volume15.47K

Average Volume (3M)58.62K

Market Cap

$2.16B

Enterprise Value$1.97B

Total Cash (Recent Filing)$95.50M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.61

Next Earnings

Aug 11, 2025

EPS Estimate

-0.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.45

Shares Outstanding32,281,760

10 Day Avg. Volume27,175

30 Day Avg. Volume58,619

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.91

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-45.24

Forecast

1Y Price Target

$93.75

Price Target Upside34.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical Trial ProgressThe PHOENIX trial has completed enrollment of 500 subjects across multiple countries, showcasing the global scale and commitment to evaluating the efficacy and safety of tinlarebant in geographic atrophy.

Price Target IncreaseAnalyst has increased the price target to $85, reflecting a more optimistic outlook.

Regulatory SupportThe FDA granted Breakthrough Therapy designation to tinlarebant for the treatment of Stargardt disease based on interim data from the ongoing Phase 3 DRAGON trial.

Bears Say

Clinical Development RisksThe next major catalysts for the shares are enrollment of the DRAGON II study and completion of the DRAGON study by year-end 2025.

Belite Bio, Inc. ADR News

Belite Bio prices 230,770 ADSs at $65.00 in registered direct offering

Belite Bio (BLTE) entered into a securities purchase agreement for the purchase and sale of 230,770 American Depositary...

1d ago

BLTE

Belite Bio Announces $15 Million Direct Offering

The latest announcement is out from Belite Bio, Inc. ADR ( ($BLTE) ). On August 6, 2025, Belite...

1d ago

BLTE

Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential

Belite Bio, Inc. ADR, the Healthcare sector company, was revisited by a Wall Street analyst on July 7....

1M ago

BLTE

Positive Buy Rating for Belite Bio Driven by Phase 3 PHOENIX Trial Milestone and Regulatory Designations

Belite Bio, Inc. ADR, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi...

1M ago

BLTE

Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant

Belite Bio, Inc. ADR ( ($BLTE) ) has shared an announcement. On July 2, 2025, Belite Bio announced...

1M ago

BLTE

Belite Bio completes enrollment in PHOENIX trial

Belite Bio (BLTE) announced the completion of enrollment in the PHOENIX trial, a global, 24-month Phase 3 pivotal...

1M ago

BLTE

Belite Bio management to meet with Maxim

Meeting to be held on June 4-5 hosted by Maxim. Published first on TheFly – the ultimate source...

2M ago

BLTE

Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating

Bruce Jackson, an analyst from Benchmark Co., maintained the Buy rating on Belite Bio, Inc. ADR (BLTE –...

3M ago

BLTE

Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Belite Bio, Inc. ADR (BLTE – Research Report)...

3M ago

BLTE

Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease

An update from Belite Bio, Inc. ADR ( ($BLTE) ) is now available. On May 21, 2025, Belite...

3M ago

BLTE

Belite Bio announces Breakthrough Therapy Designation for Tinlarebant from FDA

Belite Bio (BLTE) announced that the FDA has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of...

3M ago

BLTE

Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength

Belite Bio, Inc. ADR (($BLTE)) has held its Q1 earnings call. Read on for the main highlights of...

3M ago

BLTE

Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Belite Bio, Inc. ADR (BLTE – Research...

3M ago

BLTE

Belite Bio Advances Clinical Trials Amid Financial Challenges

Belite Bio, Inc. ADR ( ($BLTE) ) has released its Q1 earnings. Here is a breakdown of the...

3M ago

BLTE

BLTE FAQ

What was Belite Bio, Inc. ADR’s price range in the past 12 months?

Belite Bio, Inc. ADR lowest stock price was $43.70 and its highest was $86.53 in the past 12 months.

What is Belite Bio, Inc. ADR’s market cap?

Belite Bio, Inc. ADR’s market cap is $2.16B.

When is Belite Bio, Inc. ADR’s upcoming earnings report date?

Belite Bio, Inc. ADR’s upcoming earnings report date is Aug 11, 2025 which is in 3 days.

How were Belite Bio, Inc. ADR’s earnings last quarter?

Belite Bio, Inc. ADR released its earnings results on May 14, 2025. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.352 by -$0.098.

Is Belite Bio, Inc. ADR overvalued?

According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Belite Bio, Inc. ADR pay dividends?

Belite Bio, Inc. ADR does not currently pay dividends.

What is Belite Bio, Inc. ADR’s EPS estimate?

Belite Bio, Inc. ADR’s EPS estimate is -0.41.

How many shares outstanding does Belite Bio, Inc. ADR have?

Belite Bio, Inc. ADR has 32,281,760 shares outstanding.

What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?

Belite Bio, Inc. ADR reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.352. Following the earnings report the stock price went up 1.166%.

Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?

Currently, no hedge funds are holding shares in BLTE

Belite Bio, Inc. ADR Stock Smart Score

Neutral

Fundamentals

Return on Equity

-33.43%

Trailing 12-Months

Asset Growth

62.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Belite Bio, Inc. ADR

Belite Bio, Inc. ADR (BLTE) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics to address significant unmet medical needs in the fields of ophthalmology and metabolic diseases. The company is engaged in developing innovative treatments aimed at improving patient outcomes, particularly in the areas of retinal degenerative diseases such as Stargardt disease and dry age-related macular degeneration.

Belite Bio, Inc. ADR (BLTE) Earnings & Revenues

Historic Earnings Reports

BLTE Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a generally positive outlook for Belite Bio, with significant progress in clinical trials for Tinlarebant and a robust financial position. However, increased operating expenses and pending regulatory details introduce some uncertainty.View all BLTE earnings summaries

BLTE Stock 12 Month Forecast

Average Price Target

$93.75

▲(34.33% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"$40","111":"$111","57.75":"$57.8","75.5":"$75.5","93.25":"$93.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$80.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,57.75,75.5,93.25,111],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.16,61.22461538461538,65.28923076923077,69.35384615384615,73.41846153846154,77.48307692307692,81.5476923076923,85.6123076923077,89.67692307692307,93.74153846153845,97.80615384615385,101.87076923076923,105.9353846153846,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.16,59.97461538461538,62.78923076923077,65.60384615384615,68.41846153846154,71.23307692307692,74.0476923076923,76.8623076923077,79.67692307692307,82.49153846153845,85.30615384615385,88.12076923076923,90.9353846153846,{"y":93.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.16,58.91692307692308,60.67384615384615,62.43076923076923,64.1876923076923,65.94461538461539,67.70153846153846,69.45846153846153,71.21538461538461,72.9723076923077,74.72923076923077,76.48615384615385,78.24307692307693,{"y":80,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.12,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.52,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.02,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.95,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.54,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.04,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >